Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash from Investing Activities for 8 consecutive years, with $17000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 126.56% to $17000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$406000.0, a 434.21% decrease, with the full-year FY2024 number at -$215000.0, down 103.69% from a year prior.
  • Cash from Investing Activities was $17000.0 for Q3 2025 at Precision Biosciences, up from -$12000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $7.6 million in Q3 2023 to a low of -$1.7 million in Q2 2021.
  • A 5-year average of -$200894.7 and a median of -$632000.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: surged 793.94% in 2023, then tumbled 1107.69% in 2025.
  • Precision Biosciences' Cash from Investing Activities stood at -$1.5 million in 2021, then surged by 58.01% to -$632000.0 in 2022, then surged by 106.65% to $42000.0 in 2023, then crashed by 330.95% to -$97000.0 in 2024, then skyrocketed by 117.53% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Cash from Investing Activities are $17000.0 (Q3 2025), -$12000.0 (Q2 2025), and -$314000.0 (Q1 2025).